Treatment with Nicardipine Protects Brain in an Animal Model of Hypertension‐Induced Damage

Control of blood pressure protects from the development of cerebrovascular lesions and vascular dementia (VaD). This study has assessed the influence of treatment with the dihydropyridine‐type Ca^{2 +} antagonist nicardipine on brain microanatomical changes in spontaneously hypertensive rats (SHR). SHR were treated from 16th to 26th week of age with hypotensive (3 mg/Kg/day) or non‐hypotensive (0.1 mg/Kg/day) doses of nicardipine, with the non‐dihydropyridine‐type vasodilator hydralazine (10 mg/kg/day) or with vehicle (control group). Untreated age‐matched Wistar Kyoto (WKY) rats were used as a normotensive reference group. Brain volume, number of neurons, glial fibrillary‐acidic protein (GFAP)‐immunoreactive astrocytes and neurofilament 200 KDa (NFP)‐immunoreactivity (IR) were assessed in frontal and occipital cortex, hippocampus and striatum. A decrease of volume and number of nerve cells and a loss of NFP‐IR was found in the frontal and occipital cortex and in the CA1 subfield of hippocampus and in the striatum of SHR. Treatment with nicardipine countered microanatomical changes occurring in SHR, whereas hydralazine displayed a less pronounced effect. Comparatively, the non‐hypotensive dose of nicardipine was less active than the hypotensive one. The observation that equihypotensive doses of nicardipine or hydralazine did not protect brain in the same way from hypertensive brain damage suggests that lowering blood pressure is per se not enough for affording neuroprotection. The demonstration of neuroprotective effect of nicardipine suggests an use of the compound in situations in which hypertension is accompanied by the risk of brain damage.     

Outpatient Drug Treatment Program Directors' Hepatitis C‐Related Beliefs and Their Relationship to the Provision of HCV Services

The hepatitis C virus (HCV) continues to penetrate populations within the United States, especially within the drug‐abusing population. Therefore, drug users need access to HCV testing and medical care, and drug treatment programs are well situated to provide these services. Because directors of these programs are gatekeepers who can influence decisions about service provision, their beliefs about the value of providing particular services for drug treatment program patients are of considerable importance. Directors of 121 outpatient drug treatment programs throughout the United States responded to an in‐depth telephone survey that included questions on their beliefs about providing HCV services in drug treatment programs. We constructed an eight‐item scale to examine these beliefs and investigated the relationship between them and the actual HCV services offered. Overall, directors were moderately supportive of the provision of HCV medical services (on‐site or through referral) during drug treatment. Our findings indicate that there is a positive significant relationship between director's beliefs and the provision of HCV antibody testing, follow‐up testing, and the provision of HCV medication.